@borano
Review of Phase Four of the National Bowel Cancer Screening Program:
"In any decision to transition to a new test type, it is important that the test is approved by the
Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
as compared with the current iFOBT."
- Forums
- ASX - By Stock
- RHY
- Sept '21 Deloitte's review of the National Bowel Cancer Screening Program
RHY
rhythm biosciences limited
Add to My Watchlist
0.00%
!
5.3¢

Sept '21 Deloitte's review of the National Bowel Cancer Screening Program, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.77M |
Open | High | Low | Value | Volume |
5.3¢ | 5.3¢ | 5.2¢ | $429 | 8.113K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 94600 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 39318 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 94600 | 0.052 |
5 | 225097 | 0.051 |
6 | 631129 | 0.050 |
1 | 60000 | 0.048 |
2 | 59960 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 39318 | 1 |
0.054 | 98833 | 2 |
0.055 | 90673 | 1 |
0.056 | 86297 | 1 |
0.057 | 30115 | 1 |
Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |